The Moffitt Cancer Center in Tampa, Florida is seeking patients who have primary liver cancer (hepatocellular carcinoma) that has spread to other organs or is too advanced to be treated by surgery and must have had prior chemotherapy treatments.
The said patients are being recruited by Moffitt for the phase II study of the oral medication AZD6244 — an experimental anti-cancer drug that may stop the growth of cancer cells and is designed to block the pathway of a protein called MEK (important for cell survival).
According to Dr. Chris R. Garrett, principal investigator with Moffitt’s Gastrointestinal Oncology program:
“There’s no cure for …read more